Study of cadonilimab for advanced lung cancer
Part of Cancer, Lungs & breathing clinical trials.
This trial tests a new drug called cadonilimab for people with advanced non-squamous non-small cell lung cancer that has gotten worse after treatment with immunotherapy and chemotherapy. The goal is to see if it helps control the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have a type of lung cancer called non-squamous non-small cell lung cancer that has spread or cannot be removed with surgery.
- Your cancer got worse after you received a PD-1/L1 inhibitor and platinum-based chemotherapy, and you had at least 2 cycles of the immunotherapy with benefit for at least 3 months.
- Your tumor does not have certain gene changes (EGFR, ALK, ROS1, BRAF V600E).
- You are in good enough health to be up and about (ECOG score 0 or 1).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called cadonilimab combined with chemotherapy for people with advanced lung cancer who have already tried and failed immunotherapy. It aims to see if this combination can help when standard immunotherapy no longer works.
This trial tests a new immunotherapy drug called cadonilimab combined with chemotherapy as a first treatment for people with advanced non-squamous non-small cell lung cancer that does not have the PD-L1 protein. The goal is to see if this combination works better than standard treatments.
This trial tests a new immunotherapy drug (cadonilimab) combined with standard chemotherapy, given before and after surgery for lung cancer that has very low PD-L1. The goal is to see if this combination helps shrink the tumor and prevents it from coming back.
This trial tests a new drug called cadonilimab for cervical cancer that has come back or spread to other parts of the body. It aims to see how well the drug works in real-world conditions for patients who haven't had many prior treatments.
This trial tests a new immunotherapy drug, Cadonilimab, against a chemo-immunotherapy combination for people with early-stage lung cancer that can be surgically removed. The goal is to see if the new drug works better before surgery.
This trial tests a new drug (cadonilimab) plus chemotherapy for people with advanced triple-negative breast cancer that has come back or spread. It aims to see if the combination works better than standard treatment.
Hear when a new Stage IVB Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.